Low dose versus high dose stavudine for treating people with HIV infection (Q24186488)

PubMed

PubMed publication ID

25627012

22 October 2023

Martin Dedicoat

series ordinal

author given names

Martin

author last names

Dedicoat

1 reference

PubMed

PubMed publication ID

25627012

Cochrane Database of Systematic Reviews

22 October 2023

language of work or name

1 reference

28 January 2015

0 references

published in

0 references

cites work

Effect of reducing the dose of stavudine on body composition, bone density, and markers of mitochondrial toxicity in HIV-infected subjects: a randomized, controlled study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007497.PUB2

Reductions in stavudine dose might ameliorate mitochondrial-associated complications without compromising antiviral activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007497.PUB2

Design and implementation of the stavudine parallel-track program

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007497.PUB2

Assessment of mitochondrial toxicity in human cells treated with tenofovir: comparison with other nucleoside reverse transcriptase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007497.PUB2

Mitochondrial toxicity induced by nucleoside-analogue reverse-transcriptase inhibitors is a key factor in the pathogenesis of antiretroviral-therapy-related lipodystrophy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007497.PUB2

2',3'-didehydro-3'-deoxythymidine (d4T) in patients with AIDS or AIDS-related complex: a phase I trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007497.PUB2

Changes in lipid profile over 24 months among adults on first-line highly active antiretroviral therapy in the home-based AIDS care program in rural Uganda

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007497.PUB2

Postmarketing drug dosage changes of 499 FDA-approved new molecular entities, 1980-1999.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007497.PUB2

Incidence and risk factors for new-onset diabetes in HIV-infected patients: the Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007497.PUB2

Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007497.PUB2

Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007497.PUB2

The WHO public-health approach to antiretroviral treatment against HIV in resource-limited settings

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007497.PUB2

Systematic review of clinical trials evaluating low doses of stavudine as part of antiretroviral treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007497.PUB2

Pharmacology of nucleoside and nucleotide reverse transcriptase inhibitor-induced mitochondrial toxicity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007497.PUB2

Mitochondrial toxicity of antiviral drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007497.PUB2

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007497.PUB2

Safety and antiretroviral effects of combined didanosine and stavudine therapy in HIV-infected individuals with CD4 counts of 200 to 500 cells/mm3

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007497.PUB2

A randomized, dose-finding study with didanosine plus stavudine versus didanosine alone in antiviral-naive, HIV-infected Thai patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007497.PUB2

Adverse effects of reverse transcriptase inhibitors: mitochondrial toxicity as common pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007497.PUB2